Pulmonary exacerbations and parent-reported outcomes in children <6 years with cystic fibrosis

Pediatric Pulmonology

Volumn 50, Issue 3, 2015, Pages 236-243

  Brumback, Lyndia C ^a   Baines, Arthur ^a   Ratjen, Felix ^b   Davis, Stephanie D ^c   Daniel, Stephen L ^a   Quittner, Alexandra L ^d   Rosenfeld, Margaret ^e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MIAMI   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Cystic fibrosis questionnaire revised; Infants; Pulmonary exacerbations; Respiratory symptoms

Indexed keywords

ANTIBIOTIC AGENT;

ARTICLE; CFQ R RESPIRATORY SYMPTOM; CHILD; CYSTIC FIBROSIS; CYSTIC FIBROSIS QUESTIONNAIRE REVISED; DISEASE EXACERBATION; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PARENT; PHYSICAL FUNCTIONING SCORE; PRESCHOOL CHILD; PRIORITY JOURNAL; QUESTIONNAIRE; SCORING SYSTEM; SYMPTOMATOLOGY;

EID: 84923183136     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.23056     Document Type: Article

References (20)

1. Rosenfeld M, Emerson J, Williams-Warren J, Pepe M, Smith A, Montgomery AB, Ramsey B. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001;139:359-365.
2. Ferkol T, Rosenfeld M, Milla CE. Cystic fibrosis pulmonary exacerbations. J Pediatr 2006;148:259-264.
3. 1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol 2011;46:393-400.
4. Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss CH, Aiken ML. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med 2002;166:1550-1555.
5. Liou TG, Adler FR, FitzSimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001;153:345-352.
6. Sawicki GS, Rasouliyan LL, McMullen AH, Wagener JS, McColley SA, Pasta DJ, Quittner AL. Longitudinal assessment of health-related quality of life in an observational cohort of patients with cystic fibrosis. Pediatr Pulmonol 2011;6:36-44.
7. Vermeulen F, Proesmans M, Boon M, Havermans T, De Boeck K. Lung clearance index predicts pulmonary exacerbations in young patients with cystic fibrosis. Thorax 2014;69:39-45.
8. Briesacher BA, Quittner AL, Fouayzi H, Zhang J, Swensen A. Nationwide trends in the medical care costs of privately insured patients with cystic fibrosis. Pediatr Pulmonol 2011;46:770-776.
9. Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, et al. Effect of Vx-770 in persons with cystic fibrosis and the G551DCFTR mutation. N Engl J Med 2010;363:1991-2003.
10. Oermann CM, Retsch-Bogart GZ, Quittner AL, Gibson RL, McCoy KS, Montgomery AB, Cooper PJ. An 18-month study of the safety and efficacy of repeated course of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010;45:1121-1134.
11. Sly PD, Gangell CI, Chen I, Ware RS, Ranganathan S, Mott LS, Murray CP, Stick SM, AREST CF Investigators. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med 2013;368:1963-1970.
12. Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BW, EPIC Study Group. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study. Contemp Clin Trials 2009;30:256-268.
13. Wainwright CE, Vidmar S, Armstrong DS, Byrnes CA, Carlin JB, Cheney J, Cooper PJ, Grimwood K, Moodie M, Robertson CF, et al. Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in childrenwith cystic fibrosis: a randomized trial. JAMA 2011;306:163-171.
14. Rosenfeld M, Ratjen F, Brumback LC, Daniel S, Rowbotham R, McNamara S, Johnson R, Kronmal R, Davis S for the ISIS Study Group. Inhaled hypertonic saline in infants and children younger than six years of age with cystic fibrosis. JAMA 2012;307:2269-2277.
15. Quittner AL, Sawicki GS, McMullen A, Rasouliyan L, Pasta DJ, Yegin A, Konstan MW. Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national sample. Qual Life Res 2012;21:1267-1278.
16. Rabin HR, Butler SM, Wohl ME, Geller DE, Colin AA, Schidlow DV, Johnson CA, Konstan MW, Regelmann WE. Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 2004;37:400-406.
17. Byrnes CA, Vidmar S, Cheney JL, Carlin JB, Armstrong DS, Cooper PJ, Grimwood K, Moodie M, Robertson CF, Rosenfeld M, et al. Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of age. Thorax 2013;68:643-651.
18. Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Trnka J, Goss CH, Rose LM, Burns JL, Marshall BC, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2010;303: 1707-1715.
19. Anstead M, Saiman L, Mayer-Hamblett N, Lands LC, Kloster M, Goss CH, Rose L, Burns JL, Marshall B, Ratjen F. Pulmonary exacerbations in CF patients with early lung disease. J Cyst Fibros 2014;13:74-79.
20. Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the cystic fibrosis questionnairerevised respiratory symptom scale in two populations of patients with cystic fibrosis and choronic Pseudomonas aeruginosa airway infection. Chest 2009;135:1610-1618.